Small study tests drug interaction in advanced cancer patients

NCT ID NCT05063318

Completed Knowledge-focused Sponsor: PharmaMar Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This Phase 1 study looked at how the antifungal drug itraconazole affects the levels of the cancer drug lurbinectedin in 14 patients with advanced solid tumors. The goal was to understand potential drug interactions, not to treat the cancer. Results may guide future dosing and safety.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: lurbinectedin and itraconazole
What this could lead to: If successful, this could help doctors understand how to safely combine lurbinectedin with other drugs, potentially improving treatment options for advanced solid tumors.
What could go wrong: This is a very early, small Phase 1 study with only 14 participants. It focuses on drug levels, not on treating the cancer itself, so it may not lead to any direct benefit for patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMORS

Contacts and locations

Locations

Fundacion Jimenez Diaz

Madrid, 28040, Spain
Hospital HM Sanchinarro

Madrid, 28050, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.